Neoprobe’s Phase 3 Lymphoseek Study Achieves Positive Results

News — By on March 22, 2009 at 2:00 am

Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology and cardiovascular surgical and diagnostic products, announced that a multicenter Phase 3 study of Lymphoseek® has reached the accrual of 203 lymph nodes, the study’s primary accrual objective. The multi-center open label study has been conducted in patients with either breast cancer or melanoma.

Please read the complete article and let us know what you think below.

Leave a Reply

Trackbacks

Leave a Trackback